HIS
GLUE icon

Harvest Investment Services’s Monte Rosa Therapeutics GLUE Stock Holding History

Harvest Investment Services’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Buy
+19,535
New +$374K 0.06% 259

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Harvest Investment Services's GLUE Position: Q1 2026 in Review

Harvest Investment Services opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 19,535 shares worth $321K. The stake represents 0.06% of the portfolio and ranks #259 among its holdings.

190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Harvest Investment Services held 19,535 shares of Monte Rosa Therapeutics worth $321K as of Q1 2026.
  • Monte Rosa Therapeutics was a new Harvest Investment Services position in Q1 2026.
  • Monte Rosa Therapeutics made up 0.06% of Harvest Investment Services's portfolio in Q1 2026, its #259 holding.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Harvest Investment Services's 13F filing for Q1 2026, filed 15 May 2026.